Oncodesign’s General Meeting authorizes the allocation of Oncodesign Precision Medicine (OPM) shares to Oncodesign shareholders – La Bourse et la Vie TV

  • Each Oncodesign shareholder will receive one OPM share for one ONCOSIGN share held

DIJON, France–(BUSINESS WIRE)–Regulatory News:

The General Meeting of Oncodesign (Paris:ALONC) held on September 30, 2022 authorized the distribution of OPM shares to Oncodesign shareholders.

Each Oncodesign shareholder will receive one OPM share for one Oncodesign share held. No new shares will be issued as part of the listing of OPM shares on Euronext Access+.

In this context, it is specified that 6,826,110 Oncodesign shares are entitled to the exceptional distribution of bonuses and reserves decided at the General Meeting of September 30, 2022.

On this basis :

  • the cash distribution amounts to a total amount of €2,334,511.07, at the rate of approximately €0.34 per Oncodesign share entitled to the distribution;

  • and taking into account the technical fractions, 6,826,029 OPM shares will be distributed to Oncodesign shareholders, at the rate of 1 OPM share per Oncodesign share entitled to the distribution.

Shareholders holding Oncodesign shares on October 4, 2022 (at market close) will receive OPM shares (ticker MLOPM) delivered to them on October 7, 2022 (at market open).

It is recalled that Euronext Paris SA authorized, on September 26, 2022, the listing on Euronext Access + of the ordinary shares of OPM, according to the direct listing procedure within the framework of the allocation of OPM shares to shareholders of Oncodesign.

This allocation of shares will enable OPM, which has thus become independent, to work on the identification and validation of targets, as well as the development of molecules, against resistant and metastatic cancers.

A summary of the tax consequences that may apply to Oncodesign shareholders residing in France as a result of the distribution is set out in paragraph 21.8 of the information document approved by Euronext.

Shareholders should check with their usual tax adviser on the taxation applicable to their particular case. Persons who do not have their tax residence in France must also comply with the tax legislation in force in their State of residence.

Next steps until delivery of OPM shares:

  • October 4, 2022: Publication of a Euronext notice mentioning the technical reference price of the OPM share and of a new press release

  • October 5, 2022: Detachment of OPM shares – Listing of OPM on Euronext Access +

  • October 6, 2022: Record date: date of statement of the beneficiaries of the distribution of OPM shares taking into account orders executed until October 4, 2022 inclusive

  • October 7, 2022: Settlement delivery of OPM shares

About Oncodesign Precision Medicine (OPM)

Oncodesign Precision Medicine (OPM), resulting from the transfer of Biotech and AI activity from Oncodesign, is a biopharmaceutical company specializing in precision medicine to treat resistant and metastatic cancers.

OPM’s innovative technologies are: (i) OncoSNIPER for the selection of therapeutic targets using artificial intelligence; (ii) Nanocyclix® for the design and selection of small molecule macrocyclic kinase inhibitors and (iii) Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy.

From these technologies, OPM has built a portfolio of therapeutic products. Two drug candidates derived from the Nanocyclix technology should enter the clinical phase in 2022, one in partnership with SERVIER (which has exercised its exclusive worldwide license option on the program) to treat Parkinson’s disease and ODS 101 with OPM in the treatment of chronic immuno-inflammatory diseases. Finally, OPM is also collaborating with Servier for the discovery of new therapeutic targets for the treatment of canicular adenocarcinoma of the pancreas based on its Oncosniper technology. In addition, OPM is looking for a partner for Florepizol, a specific radiotracer for the mutated EGFR target, which has passed its Phase 1. Two projects are in early partnership with TIUM BIO (pulmonary fibrosis) and Sengines in oncology. Finally, OPM has a large portfolio of early projects with Nanocyclix® and Theranostics in oncology. With this portfolio of molecules and diversified therapeutic targets, OPM’s mission is to discover effective therapies to treat resistant and advanced cancers. Based in Dijon, at the heart of the university and hospital center, OPM has 25 employees.

More information : opm.oncodesign.com

About Oncodesign

Oncodesign is a biopharmaceutical company specializing in precision medicine founded in 1995 by its current CEO and majority shareholder, it has been listed on Euronext Growth Paris since April 2014. Its mission is the discovery of effective therapies against cancer and other diseases without solutions. therapies. With experience acquired from more than 1,000 customers, including the world’s largest pharmaceutical companies, and relying on a unique technological platform, combining artificial intelligence, medicinal chemistry, pharmacology, regulatory bioanalysis and advanced medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates up to the clinical phase stage. Oncodesign has configured its organization to offer innovative services to its customers and licenses on its proprietary molecules. Applied to kinase inhibitors, molecules which represent a market estimated at more than 65 billion dollars by 2027 and nearly 25% of R&D investments in the pharmaceutical industry, Oncodesign’s technology has already made it possible to target several molecules of interest with high therapeutic potential, in oncology and outside oncology, and to sign partnerships with international pharmaceutical groups. In 2022, Oncodesign announced the spin-off of its Biotech and Artificial Intelligence activities under the name ‘Oncodesign Precision Medicine’ (OPM).

More information on the site www.oncodesign.com.

Forward-looking statements

This document contains forward-looking statements and estimates with respect to the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “expects”, “projects”, “plans”, “seeks”, “estimates”, “may”, “wants” and “continues” and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company’s control. Accordingly, the actual results, financial conditions, performance or achievements of the Company, or industry results, may differ materially from any future results, performance or achievements as expressed or implied by such statements, forecasts and estimates Given these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of the publication of this document. The Company disclaims any obligation to update any such forward-looking statements, forecasts or estimates to reflect any change in the Company’s expectations with respect thereto, or any change in events, conditions or circumstances on which such statements, forecasts or estimates are based. , except as required by French law.

contacts

Oncodesign
Philippe Genne

Chairman and CEO

Such. : +33 (0)3 80 78 82 60

investors@oncodesign.com

NOTewCap
Investor Relations

Mathilde Bohin

Such. : +33 (0)1 44 71 94 95

oncodesign@newcap.eu

NewCap
Media Relations

Arthur Rusty

Such. : +33 (0)1 44 71 00 15

oncodesign@newcap.eu

We wish to give thanks to the author of this post for this incredible web content

Oncodesign’s General Meeting authorizes the allocation of Oncodesign Precision Medicine (OPM) shares to Oncodesign shareholders – La Bourse et la Vie TV


Our social media profiles here as well as other pages on related topics here.https://www.ai-magazine.com/related-pages/